公开(公告)号：US20150031050A1

公开(公告)日：2015-01-29

申请号：US14455951

申请日：2014-08-11

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Ting LI ,  Kam Wai WONG ,  Zhihong JIANG ,  Hua ZHOU

IPC: G01N33/573

CPC classification number: G01N33/573 ,  A61K31/352 ,  A61K31/4188 ,  G01N33/574 ,  G01N2333/91205 ,  G01N2333/91215 ,  G01N2500/04 ,  G01N2800/102 ,  G01N2800/44

Abstract: Uses and applications derived from the discovery of a novel binding site of IKK-β, such as method of screening a therapeutic agent as drug candidate for treating cancer, inflammation, or other diseases/disorders, are provided.

Abstract translation: 提供了从发现IKK-和bgr的新结合位点衍生的用途和应用，例如筛选治疗剂作为治疗癌症，炎症或其它疾病/障碍的候选药物的方法。

公开(公告)号：US20170056390A1

公开(公告)日：2017-03-02

申请号：US14925962

申请日：2015-10-28

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU

IPC: A61K31/4745

CPC classification number: A61K31/4745

Abstract: The present invention discloses a method of treating cancer and/or multidrug-resistant cancer, comprising administering an effective amount of hernandezine or thalidezine. A pharmaceutical composition comprising hernandezine or thalidezine admixed with a pharmaceutical carrier for treating cancers and/or multidrug-resistant cancer is also disclosed.

Abstract translation: 本发明公开了一种治疗癌症和/或多药耐药性癌症的方法，其包括施用有效量的涕灭威或沙利度胺。 还公开了包含与用于治疗癌症和/或多药耐药性癌症的药物载体混合的栀子苷或沙利度胺的药物组合物。

公开(公告)号：US20160037757A1

公开(公告)日：2016-02-11

申请号：US14620141

申请日：2015-02-11

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Ting LI ,  Kam Wai WONG ,  Zhihong JIANG ,  Hua ZHOU

IPC: A01K67/027 ,  A61K49/00

CPC classification number: A01K67/0278 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0368 ,  A61K49/0008 ,  G01N33/573 ,  G01N33/574 ,  G01N2333/91215 ,  G01N2800/102 ,  G01N2800/44

Abstract: The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-βC46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-β protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-β. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-βC46A mutants.

Abstract translation: 本发明提供了一种用于鉴定和确定延迟型超敏反应（DTH）和通过IKK-和bgr C46A突变体的活化介导的其它炎性或癌性疾病的测试化合物的治疗或预防活性的体内平台。 本发明的体内平台是非人转基因哺乳动物，例如小鼠模型，在IKK-和bgr中被半胱氨酸残基替换为丙氨酸的位点定向诱变; 蛋白激酶。 通过特异设计的靶向载体引入定点诱变，所述靶向载体在编码IKK-＆bgr的Ikbkb基因的外显子3中含有颠换。 本发明还提供了产生转基因哺乳动物以及用于测定和鉴定可以抑制IKK-Bgr C46A突变体活化的化合物的方法。

公开(公告)号：US20170014375A1

公开(公告)日：2017-01-19

申请号：US14799541

申请日：2015-07-14

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU ,  Su-Wei XU

IPC: A61K31/352

CPC classification number: A61K31/352

Abstract: The present invention provides a compound of formula (I) as a SERCA inhibitor for treating cancers, a pharmaceutical composition comprising said compound, and methods of using said compound for treating cancers and/or inducing cell death in cells of said cancers. Said cancers include but not limited to cervical, lung, liver, breast, and prostate cancer. Said cancers also include drug-resistant and/or apoptosis-resistant cancers such as isogenic drug-resistant colon cancer. The subject being administered with said compound or the composition comprising thereof can be human or animal subject. Said methods for treating cancers and/or inducing cell death can be a targeting treatment for certain cancers.

Abstract translation: 本发明提供了作为用于治疗癌症的SERCA抑制剂的式（I）化合物，包含所述化合物的药物组合物，以及使用所述化合物治疗癌症和/或诱导所述癌症细胞中的细胞死亡的方法。 所述癌症包括但不限于宫颈癌，肺癌，肝癌，乳腺癌和前列腺癌。 所述癌症还包括耐药性和/或细胞凋亡抵抗性癌症，例如同基因耐药结肠癌。 给予所述化合物或包含其的组合物的受试者可以是人或动物受试者。 用于治疗癌症和/或诱导细胞死亡的所述方法可以是某些癌症的靶向治疗。

公开(公告)号：US20160106733A1

公开(公告)日：2016-04-21

申请号：US14985419

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU ,  Jingrong WANG

IPC: A61K31/4748 ,  A61K31/4725

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

公开(公告)号：US20150133492A1

公开(公告)日：2015-05-14

申请号：US14526539

申请日：2014-10-29

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Zhi Hong JIANG ,  Liang LIU ,  Wai Kit CHAN ,  Xiao Jun YAO

IPC: A61K31/4725

CPC classification number: A61K31/4725

Abstract: This invention is directed to the use of N-desmethyldauricine, a novel autophagy enhancer, in treating cancers or neurodegenerative conditions.

Abstract translation: 本发明涉及一种新型自噬增强剂N-去甲基牛磺酸在治疗癌症或神经变性疾病中的应用。

公开(公告)号：US20160113922A1

公开(公告)日：2016-04-28

申请号：US14985417

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU ,  Jingrong WANG

IPC: A61K31/4745 ,  A61K31/4725

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

公开(公告)号：US20160106732A1

公开(公告)日：2016-04-21

申请号：US14985412

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU ,  Jingrong WANG

IPC: A61K31/4748 ,  A61K31/4725

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

公开(公告)号：US20150050363A1

公开(公告)日：2015-02-19

申请号：US14231671

申请日：2014-03-31

Applicant: Macau University of Science and Technology

Inventor： Yuen Kwan LAW ,  An Guo WU ,  Kam Wai WONG ,  Liang LIU

IPC: A61K36/69

CPC classification number: A61K36/69 ,  A61K31/704

Abstract: Use and application of Onjisaponin B derived and isolated from Radix Polygalae as novel autophagy enhancer are provided. A method of preventing, treating and/or delaying the onset of neurodegenerative diseases comprising administering an effective amount of Onjisaponin B is also provided.

Abstract translation: 本发明提供了从根部提取和分离的Onjisaponin B作为新的自噬增强剂的应用和应用。 还提供了预防，治疗和/或延缓神经变性疾病发作的方法，包括给予有效量的Onjisaponin B.

公开(公告)号：US20160106730A1

公开(公告)日：2016-04-21

申请号：US14985414

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU ,  Jingrong WANG

IPC: A61K31/4725

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.